David Schnell October 19, 2020 Oct 19, 2020 - NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, a Novel Dual Antagonist Antibody David Schnell October 19, 2020
David Schnell August 31, 2020 Aug 29, 2020 - NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study of Aldafermin at Digital International Liver Congress (ILC) 2020 and Enrollment Completed in Phase 2b ALPINE Study David Schnell August 31, 2020
David Schnell July 27, 2020 July 27, 2020 - NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) David Schnell July 27, 2020
David Schnell June 15, 2020 June 15, 2020 - Iveric Bio Announces Positive Zimura 18 Month Data Supporting Efficacy Findings with Favorable Safety Profile in Geographic Atrophy Secondary to AMD in a Phase 3 Trial David Schnell June 15, 2020
David Schnell June 8, 2020 June 8, 2020 - Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis David Schnell June 8, 2020
David Schnell May 8, 2020 May 8, 2020 - AtriCure Announces Results from CONVERGE IDE Clinical Trial David Schnell May 8, 2020
David Schnell February 24, 2020 February 24, 2020 - NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study of Aldafermin in NASH Patients David Schnell February 24, 2020
David Schnell February 11, 2020 February 11, 2020 - NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS) David Schnell February 11, 2020
David Schnell February 3, 2020 February 3, 2020 - Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis David Schnell February 3, 2020
David Schnell January 7, 2020 January 7, 2020 - AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol David Schnell January 7, 2020
David Schnell October 7, 2019 October 7, 2019 - NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH David Schnell October 7, 2019
David Schnell October 3, 2019 October 3, 2019 - NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting David Schnell October 3, 2019
David Schnell August 12, 2019 August 12, 2019 - AtriCure Enters Into Definitive Agreement to Acquire SentreHEART David Schnell August 12, 2019
David Schnell June 5, 2019 June 5, 2019 - NGM Bio to Present New Data from Phase 1b Study of NGM313 at the American Diabetes Association David Schnell June 5, 2019
David Schnell May 20, 2019 May 20, 2019 - New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® in Patients with Refractory MAC Lung Disease David Schnell May 20, 2019
David Schnell May 9, 2019 May 9, 2019 - NinePoint Medical Announces Publication of 1000 Patient Registry Study David Schnell May 9, 2019
David Schnell April 8, 2019 April 8, 2019 - NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019 David Schnell April 8, 2019
David Schnell April 8, 2019 April 8, 2019 - Insmed Provides Update on ARIKAYCE® U.S. Launch David Schnell April 8, 2019
David Schnell April 3, 2019 April 3, 2019 - NGM Announces Pricing of Initial Public Offering David Schnell April 3, 2019
David Schnell March 20, 2019 March 20, 2019 - Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022 David Schnell March 20, 2019